Drug Profile
ONCOS 102
Alternative Names: Ad5/3-D24-GMCSF; AdV5/3-D24-GM-CSF; CGTG-102; ONCOS-102Latest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator Oncos Therapeutics
- Developer AstraZeneca; Ludwig Institute for Cancer Research; Oncos Therapeutics; SOTIO; Targovax
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant-mesothelioma
- Phase I/II Colorectal cancer; Ovarian cancer
- Phase I Malignant melanoma
- Discontinued Prostate cancer; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 22 Jun 2023 Agenus and Targovax withdraws a phase II trial prior to enrolment in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic, Treatment-resistant, Monotherapy, Second-line therapy or greater) (Intratumoral, Injection) due to strategic reason (NCT05561491)
- 02 Jun 2023 Immunogenicity and efficacy data from the phase I/II MESOS trial in Mesothelioma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 25 Jun 2022 Targovax and MedImmune complete a phase I/II trial for Colorectal cancer and Ovarian Cancer (Combination therapy, Second-line therapy or greater) in USA (NCT02963831)